Pat Maciejewski

Statistics

Publications

Citations

361

H-Index

Active since

2015

Affiliations

Gilead Sciences (United States)(Current)

Pat Maciejewski is an author at Gilead Sciences (United States) specializing in medicinal chemistry, pharmacology, and selective tyrosine kinase inhibitors.

Publications per year

2015–2017

Publications

Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

Verena Petzer, Matthew R. Warr, David Haschka et al. · Blood · 2017 · 221 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834

Wendy B. Young, J A Barbosa, Peter Blomgren et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 65 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability

Wendy B. Young, J A Barbosa, Peter Blomgren et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 41 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties

Xiaojing Wang, J A Barbosa, Peter Blomgren et al. · ACS Medicinal Chemistry Letters · 2017 · 34 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

1–4 of 4